*Day 1 sample obtained approximately 6 hours after presentation and before thyroid-hormone replacement. †Day 2 and Day 3 samples were obtained before the daily levothyroxine dose. Local laboratory reference intervals: TSH, 0.27–4.2 mIU/L; fT3, 2.00–4.40 pg/mL; fT4, 0.80–1.76 ng/dL. fT3: free triiodothyronine; fT4: free thyroxine; TSH: thyroid-stimulating hormone.
Declarations
Acknowledgments
During the preparation of this work, the authors used ChatGPT (OpenAI) and Antigravity to assist with language refinement and editorial organisation. These tools were not used to make clinical decisions or determine the scientific conclusions. The authors independently reviewed and verified the clinical data, analyses, figure annotations, and references, edited the final text, and take full responsibility for the manuscript.
Author contributions
ABD: Conceptualization, Data curation, Writing—original draft, Writing—review & editing. HG: Data curation, Writing—review & editing. TE: Investigation, Writing—review & editing. SB: Investigation, Writing—review & editing. DK: Supervision, Writing—review & editing. All authors read and approved the submitted version.
Conflicts of interest
The authors declare that they have no conflicts of interest.
Ethical approval
This case report was prepared in accordance with the Declaration of Helsinki. All clinical information was obtained during routine clinical care and was de-identified. Under the institutional policy applicable at Kocaeli City Hospital, formal ethics committee approval is not required for publication of a single anonymised case report.
Consent to participate
As the patient died during the admission, written informed consent to participate was obtained from the patient’s next of kin on his behalf.
Consent to publication
As the patient died during the admission, written informed consent for publication of the anonymised case details and images was obtained from the patient’s next of kin.
Availability of data and materials
The de-identified clinical, laboratory, electrocardiographic and imaging data supporting this case report are available from the corresponding author upon reasonable request, subject to institutional approval and patient-privacy restrictions.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Pachucki J, Burmeister LA, Larsen PR. Thyroid Hormone Regulates Hyperpolarization-Activated Cyclic Nucleotide-Gated Channel (HCN2) mRNA in the Rat Heart.Circ Res. 1999;85:498–503. [DOI] [PubMed]
Ojamaa K, Sabet A, Kenessey A, Shenoy R, Klein I. Regulation of Rat Cardiac Kv1.5 Gene Expression by Thyroid Hormone Is Rapid and Chamber Specific.Endocrinology. 1999;140:3170–6. [DOI] [PubMed]
Matos LFS, Dos Santos EB, Rocha CSG, Gomes JVS, Marques NRM, Souza DS. Thyroid hormone deficiency-induced cardiac ion channel dysfunction: Molecular mechanisms and arrhythmic implications.Curr Top Membr. 2026;97:59–87. [DOI] [PubMed]
Alwan H, Hysaj O, Gencer B, Duntas L, Rodondi N. Thyroid dysfunction and cardiovascular disease.Eur Heart J. 2026;47:2606–23. [DOI] [PubMed] [PMC]
Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay.J Am Coll Cardiol. 2019;74:e51–156. [DOI] [PubMed]
Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.Eur Heart J. 2021;42:3427–520. [DOI] [PubMed]
Schoenmakers N, de Graaff WE, Peters RH. Hypothyroidism as the cause of atrioventricular block in an elderly patient.Neth Heart J. 2008;16:57–9. [DOI] [PubMed] [PMC]
Seol SH, Kim DI, Park BM, Kim DK, Song PS, Kim KH, et al. Complete Atrioventricular Block Presenting With Syncope Caused by Severe Hypothyroidism.Cardiol Res. 2012;3:239–41. [DOI] [PubMed] [PMC]
Ozcan KS, Osmonov D, Erdinler I, Altay S, Yildirim E, Turkkan C, et al. Atrioventricular block in patients with thyroid dysfunction: Prognosis after treatment with hormone supplementation or antithyroid medication.J Cardiol. 2012;60:327–32. [DOI] [PubMed]
Yilmaz S, Kilinc M, Adali MK, Buber I, Dursunoglu D. Incidence and Predictors of Complete Atrioventricular Conduction Recovery Among Patients With Heart Block.Future Cardiol. 2021;17:677–83. [DOI] [PubMed]
Kataoka S, Kobayashi Y, Isogai T, Tanno K, Fukamizu S, Watanabe N, et al. Permanent pacemaker implantation and its predictors in patients admitted for complete atrioventricular block: a report from the Tokyo Cardiovascular Care Unit Network multi-center registry.Heart Vessels. 2020;35:1573–82. [DOI] [PubMed]
Taylor P, Gibb F, Medici M, Parekh D, Moran C, Duntas L, et al. Management of endocrine emergencies: joint consensus statement for management of myxoedema coma.Eur Thyroid J. 2026;15:ETJ260044. [DOI] [PubMed] [PMC]
Zhang Y, Chu L, Han H. Myxedema coma: challenges and future directions, a systematic survey and review.Thyroid Res. 2025;18:48. [DOI] [PubMed] [PMC]
Popoveniuc G, Chandra T, Sud A, Sharma M, Blackman MR, Burman KD, et al. A Diagnostic Scoring System for Myxedema Coma.Endocr Pract. 2014;20:808–17. [DOI] [PubMed]
Russotto V, Myatra SN, Laffey JG, Tassistro E, Antolini L, Bauer P, et al.; INTUBE Study Investigators. Intubation Practices and Adverse Peri-intubation Events in Critically Ill Patients From 29 Countries.JAMA. 2021;325:1164–72. [DOI] [PubMed] [PMC]
Kurniawan LB. Non-thyroidal illness (euthyroid sick) syndrome: Laboratory aspects and clinical significance in critically ill patients and other diseases – A narrative review.J Crit Care Med. 2026;12:46–55. [DOI] [PubMed] [PMC]
